A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma

This study has been completed.
Sponsor:
Information provided by:
PharmaMar
ClinicalTrials.gov Identifier:
NCT00229203
First received: September 27, 2005
Last updated: December 14, 2009
Last verified: December 2009
  Purpose

This is a phase II study to determine the efficacy following treatment with Aplidin® 5 mg/m2, given as a 3 hours intravenous infusion every 2 weeks, in patients with relapsed or refractory multiple myeloma (MM).


Condition Intervention Phase
Multiple Myeloma
Drug: Plitidepsin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: "Phase II Multicenter, Open-Label, Clinical and Pharmacokinetic Study of Aplidin® As A 3-Hour Infusion Every 2 Weeks Alone or in Combination With Dexamethasone, in Pre-Treated Patients With Relapsing or Refractory Multiple Myeloma."

Resource links provided by NLM:


Further study details as provided by PharmaMar:

Primary Outcome Measures:
  • Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response [ Time Frame: Every 2 weeks until progression or death occurs. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to Progression (TTP) [ Time Frame: Every 2 weeks until progression or death due to progression occurs. Median TTP and TTP rates at 3 months and 6 months were assessed. ] [ Designated as safety issue: No ]
  • Progression Free Survival (PFS) [ Time Frame: Every 2 weeks until progression or death occurs. Median PFS and PFS rates at 3 months and 6 months were assessed. ] [ Designated as safety issue: No ]
  • Number of Patients With Overall Survival (OS) [ Time Frame: Start of treatment to death. At each patient visit while on treatment, then every 3m during follow-up. Median OS and OS rates at 6 months and 12 months were assessed. ] [ Designated as safety issue: No ]

Enrollment: 51
Study Start Date: February 2005
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Plitidepsin
    3-hour infusion every 2 weeks alone or in combination with dexamethasone
Detailed Description:

This is a phase II study to determine the efficacy following treatment with Aplidin® 5 mg/m2, given as a 3 h iv infusion every 2 weeks, in patients with relapsed or refractory multiple myeloma (MM) and to obtain the following :

  • Additional pharmacokinetic information for Aplidin® given as 3-hour IV infusion every 2 weeks in patients with MM.
  • To obtain additional genomic and pharmacodynamics information on MM and Aplidin.
  • To assess the safety and tolerability of Aplidin® given as 3-hour IV infusion every 2 weeks in patients with MM alone or in combination with dexamethasone given orally as a 20 mg daily for 4 days
  • To determine the response rate in the second cohort of patients following treatment with Aplidin®, given as a 3 hour infusion every 2 weeks, plus dexamethasone given orally as a 20 mg daily for 4 days, starting the same day of Aplidin® administration, as a second treatment stage in patients with suboptimal response to Aplidin® as single agent (progressive disease after three cycles or stable disease after four cycles).
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. Written informed consent obtained from the patient before starting any study-specific procedure. If any patient is unable to give consent, it may be obtained from the patient's legal representative if in accordance with local laws and regulations
  2. Age ≥ 18 years
  3. Performance status Eastern Cooperative Oncology Group (ECOG) ≤ 2
  4. Life expectancy ≥ 3 months.
  5. Patient was previously diagnosed with MM based on standard criteria and currently requires treatment because MM relapses following a response to standard chemotherapy or high-dose chemotherapy, or MM is refractory (i.e., failure to achieve at least complete response (CR), partial response (PR) or stable disease (SD)) to their most recent chemotherapy.
  6. Patient has measurable disease, defined as follows:

    • For secretory multiple myeloma, measurable disease is defined as any quantifiable serum monoclonal protein value and, where applicable, urine light-chain excretion of ≥ 200 mg/24 hours.
    • For oligo or non-secretory multiple myeloma, measurable disease is defined by the presence of soft tissue (not bone) plasmacytomas as determined by clinical examination or applicable radiographs (i.e. Magnetic resonance imaging (MRI), Computerized Axial Tomography (CT-Scan)).
  7. Recovery from any non-hematological toxicity derived from previous treatments. The presence of alopecia and National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade < 2 sensitive peripheral neuropathy is allowed.
  8. Patient has the following laboratory values within 14 days before day 1, cycle 1:

    • Platelet count ≥ 50 x109/L, hemoglobin ≥ 8.0 g/dl and absolute neutrophil count (ANC) ≥ 1.0x109/L; lower values may be accepted if clearly are due to bone marrow involvement by multiple myeloma.
    • Corrected serum calcium < 14mg/dL.
    • Aspartate transaminase (AST): ≤ 2.5 x the upper limit of normal.
    • Alanine transaminase (ALT): ≤ 2.5 x the upper limit of normal.
    • Total bilirubin: ≤ 1.5 x the upper limit of normal.
    • Calculated Creatinine clearance: ≥ 40 mL/minute (by means of Crockoft and Gault´s formula).
  9. Left ventricular ejection fraction within normal limits.

Exclusion criteria

  1. Prior therapy with Aplidin®.
  2. Pregnant or lactating women; men and women of reproductive potential who are not using effective contraceptive methods (double barrier method, intrauterine device, oral contraception)
  3. History of another neoplastic disease. The exceptions are:

    • non-melanoma skin cancer,
    • carcinoma in situ of uterine cervix,
    • any other cancer curatively treated and no evidence of disease for at least 10 years.
  4. Other relevant diseases or adverse clinical conditions:

    • History or presence of unstable angina, myocardial infarction, valvular heart disease or congestive heart failure.
    • Previous mediastinal radiotherapy.
    • Uncontrolled arterial hypertension despite optimal medical therapy.
    • Previous treatment with doxorubicin at cumulative doses in excess of 400 mg/m².
    • Symptomatic arrhythmia or any arrhythmia requiring treatment.
    • History of significant neurological or psychiatric disorders
    • Active infection
    • Patient is known to be human immunodeficiency virus (HIV) positive, Hepatitis B surface antigen-positive or active hepatitis C infection.
    • Myopathy or any clinical situation that causes significant and persistent elevation of creatine kinase (CK)(>2.5 ULN in two different determinations performed with one week apart)
    • Significant non-neoplastic liver disease (e.g. cirrhosis, active chronic hepatitis)
    • Uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or hyperthyroidism) (i.e. requiring relevant changes in medication within the last month, or hospital admission within the last 3 months)
  5. Limitation of the patient's ability to comply with the treatment or follow-up protocol.
  6. Treatment with any investigational product in the 30 days period before inclusion in the study or radiotherapy in the 4 weeks before inclusion in the study. Other previous treatments should have been completed 3 weeks before inclusion in the study, and in case of high dose chemotherapy, 8 weeks.
  7. Known hypersensitivity to Aplidin®, mannitol, cremophor, or ethanol or dexamethasone.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00229203

Locations
United States, Massachusetts
Jerome Lipper Multiple Myeloma Center - Dept of Medical Oncology - Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
PharmaMar
Investigators
Study Chair: Paul Richardson, MD Chief division hematological malignancies - Medical Oncology - Dana Farber Cancer Institute - Harvard Medical School, Boston
  More Information

No publications provided

Responsible Party: PharmaMar USA Inc.
ClinicalTrials.gov Identifier: NCT00229203     History of Changes
Other Study ID Numbers: APL-B-014-03
Study First Received: September 27, 2005
Results First Received: August 31, 2009
Last Updated: December 14, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by PharmaMar:
Myeloma
Aplidin
Plitidepsin
PharmaMar

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 15, 2014